Sanofi acquires US biopharma firm Blueprint Medicines for $9.1 billion
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
This strategic move positions Sudeep Pharma to seamlessly integrate high-end premix capabilities with its mineral portfolio
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
Isotretinoin capsules are indicated to treat severe, disfiguring nodular acne
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
Lupin is set to become first Indian company to fully integrate Honeywell’s Solstice® Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants
Subscribe To Our Newsletter & Stay Updated